These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24517629)

  • 1. Confinement effects on drugs in thermally hydrocarbonized porous silicon.
    Mäkilä E; Ferreira MP; Kivelä H; Niemi SM; Correia A; Shahbazi MA; Kauppila J; Hirvonen J; Santos HA; Salonen J
    Langmuir; 2014 Mar; 30(8):2196-205. PubMed ID: 24517629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Surface Chemistry on Ibuprofen Adsorption and Confinement in Mesoporous Silicon Microparticles.
    Mäkilä E; Kivelä H; Shrestha N; Correia A; Kaasalainen M; Kukk E; Hirvonen J; Santos HA; Salonen J
    Langmuir; 2016 Dec; 32(49):13020-13029. PubMed ID: 27951684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microfluidic templated mesoporous silicon-solid lipid microcomposites for sustained drug delivery.
    Liu D; Herranz-Blanco B; Mäkilä E; Arriaga LR; Mirza S; Weitz DA; Sandler N; Salonen J; Hirvonen J; Santos HA
    ACS Appl Mater Interfaces; 2013 Nov; 5(22):12127-34. PubMed ID: 24175755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectroscopic Investigation of the Formation and Disruption of Hydrogen Bonds in Pharmaceutical Semicrystalline Dispersions.
    Van Duong T; Reekmans G; Venkatesham A; Van Aerschot A; Adriaensens P; Van Humbeeck J; Van den Mooter G
    Mol Pharm; 2017 May; 14(5):1726-1741. PubMed ID: 28363028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs.
    Wang F; Hui H; Barnes TJ; Barnett C; Prestidge CA
    Mol Pharm; 2010 Feb; 7(1):227-36. PubMed ID: 19874003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles.
    Tahvanainen M; Rotko T; Mäkilä E; Santos HA; Neves D; Laaksonen T; Kallonen A; Hämäläinen K; Peura M; Serimaa R; Salonen J; Hirvonen J; Peltonen L
    Int J Pharm; 2012 Jan; 422(1-2):125-31. PubMed ID: 22063301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow coloration phenomena of incorporated indomethacin into folded sheet mesoporous materials.
    Tanabe S; Higashi K; Umino M; Limwikrant W; Yamamoto K; Moribe K
    Int J Pharm; 2012 Jun; 429(1-2):38-45. PubMed ID: 22446085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the dissolution rate of hydrophobic drugs through encapsulation in porous lactose as a new biocompatible porous carrier.
    Ebrahimi A; Saffari M; Langrish T
    Int J Pharm; 2017 Apr; 521(1-2):204-213. PubMed ID: 28232266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of biopolymer-modified porous silicon microparticles for wound healing applications.
    Mori M; Almeida PV; Cola M; Anselmi G; Mäkilä E; Correia A; Salonen J; Hirvonen J; Caramella C; Santos HA
    Eur J Pharm Biopharm; 2014 Nov; 88(3):635-42. PubMed ID: 25305585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amorphous formulations of indomethacin and griseofulvin prepared by electrospinning.
    Lopez FL; Shearman GC; Gaisford S; Williams GR
    Mol Pharm; 2014 Dec; 11(12):4327-38. PubMed ID: 25317777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles.
    Limnell T; Riikonen J; Salonen J; Kaukonen AM; Laitinen L; Hirvonen J; Lehto VP
    Int J Pharm; 2007 Oct; 343(1-2):141-7. PubMed ID: 17600644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bare and amino modified mesoporous silica@poly(ethyleneimine)s xerogel as indomethacin carrier: Superiority of amino modification.
    Li J; Xu L; Wang H; Yang B; Liu H; Pan W; Li S
    Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():710-716. PubMed ID: 26652425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid-State NMR Investigation of Drug-Excipient Interactions and Phase Behavior in Indomethacin-Eudragit E Amorphous Solid Dispersions.
    Lubach JW; Hau J
    Pharm Res; 2018 Feb; 35(3):65. PubMed ID: 29464409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanostructures and Dynamics of Isochorically Confined Amorphous Drug Mediated by Cooling Rate, Interfacial, and Intermolecular Interactions.
    Zhang C; Sha Y; Zhang Y; Cai T; Li L; Zhou D; Wang X; Xue G
    J Phys Chem B; 2017 Nov; 121(47):10704-10716. PubMed ID: 29111765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gel Formation Induced Slow Dissolution of Amorphous Indomethacin.
    Heng W; Wei Y; Xue Y; Cheng H; Zhang L; Zhang J; Gao Y; Qian S
    Pharm Res; 2019 Sep; 36(11):159. PubMed ID: 31515697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T
    Okada K; Hirai D; Hayashi Y; Kumada S; Kosugi A; Onuki Y
    Chem Pharm Bull (Tokyo); 2019; 67(6):580-586. PubMed ID: 31155564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionalization of alkyne-terminated thermally hydrocarbonized porous silicon nanoparticles with targeting peptides and antifouling polymers: effect on the human plasma protein adsorption.
    Wang CF; Mäkilä EM; Bonduelle C; Rytkönen J; Raula J; Almeida S; Närvänen A; Salonen JJ; Lecommandoux S; Hirvonen JT; Santos HA
    ACS Appl Mater Interfaces; 2015 Jan; 7(3):2006-15. PubMed ID: 25539741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro dissolution methods for hydrophilic and hydrophobic porous silicon microparticles.
    Mönkäre J; Riikonen J; Rauma E; Salonen J; Lehto VP; Järvinen K
    Pharmaceutics; 2011 Jun; 3(2):315-25. PubMed ID: 24310498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesoporous silicon (PSi) for sustained peptide delivery: effect of psi microparticle surface chemistry on peptide YY3-36 release.
    Kovalainen M; Mönkäre J; Mäkilä E; Salonen J; Lehto VP; Herzig KH; Järvinen K
    Pharm Res; 2012 Mar; 29(3):837-46. PubMed ID: 22033881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular interactions of surface modified nanoporous silicon particles.
    Bimbo LM; Sarparanta M; Mäkilä E; Laaksonen T; Laaksonen P; Salonen J; Linder MB; Hirvonen J; Airaksinen AJ; Santos HA
    Nanoscale; 2012 May; 4(10):3184-92. PubMed ID: 22508528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.